CANF Stock Risk & Deep Value Analysis
Can Fite Biopharma Ltd
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About CANF Stock
We analyzed Can Fite Biopharma Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CANF through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is CANF Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
High
Competitive Risk
High
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for CANF?
- âš
Further dilutive equity offerings to fund operations beyond current runway.
- âš
Negative or inconclusive clinical trial results for Namodenoson.
- âš
Failure to secure additional financing, leading to potential delisting or bankruptcy.
- âš
Increased competitive pressure in liver cancer and NASH markets.
Unlock CANF Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Can Fite Biopharma Ltd (CANF) Do?
Market Cap
$9.55M
Sector
Healthcare
Industry
Biotechnology
Employees
5
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Visit Can Fite Biopharma Ltd WebsiteIs CANF Stock Undervalued?
Unlock the full AI analysis for CANF
Get the complete DVR score, risk analysis, and more
Does CANF Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Moat Sources
1 Identified
The potential moat relies solely on the successful clinical development and commercialization of its drug candidates, which is highly uncertain. With regulatory setbacks and significant financial challenges, the durability is very low.
Moat Erosion Risks
- •Clinical trial failures or inconclusive results for lead drug candidates.
- •Inability to secure sufficient funding to complete clinical development and achieve commercialization.
- •Emergence of superior or more advanced competing treatments from larger pharmaceutical companies.
- •Patent expiry or challenges to existing IP.
CANF Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive CANF Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated Early May 2026), focusing on cash runway updates.
- •Updates on ongoing Phase 2/3 trials for Namodenoson (potential for early readouts, though unlikely to be definitive).
Medium-Term (6-18 months)
- •Phase 2/3 clinical trial data for Namodenoson in liver cancer or NASH (6-18 months).
- •Potential strategic partnership announcement for Namodenoson, contingent on positive trial data.
Long-Term (18+ months)
- •Regulatory submission (NDA) and approval for Namodenoson in target indications (18+ months, highly speculative).
- •Significant market penetration of Namodenoson post-approval, establishing competitive positioning.
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CANF?
- ✓
Significant positive, statistically robust Phase 2/3 clinical trial data for Namodenoson.
- ✓
Announcement of a major strategic partnership with a large pharmaceutical company, including substantial upfront payments.
- ✓
Successful completion of a major financing round that is non-dilutive or minimally dilutive, extending cash runway significantly (e.g., 2+ years).
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CANF (Can Fite Biopharma Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
